Advertisement
UK markets open in 1 hour 31 minutes

  • NIKKEI 225

    37,651.77
    -808.31 (-2.10%)
     

  • HANG SENG

    17,270.64
    +69.37 (+0.40%)
     

  • CRUDE OIL

    82.95
    +0.14 (+0.17%)
     

  • GOLD FUTURES

    2,329.10
    -9.30 (-0.40%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,370.30
    -2,220.39 (-4.14%)
     

  • CMC Crypto 200

    1,387.68
    -36.42 (-2.56%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

BUZZ-Regulus Inc: Drug to be tested by AstraZeneca

Reuters - UK Focus

** Drug developer's shares up 9.4 pct at $17.45 in extended trading

** Company says Astrazeneca Plc (NYSE: AZN - news) selected its experimental drug, RG-125, for early-stage trial on Non Alcoholic Steatohepatitis (NASH) patients, as part of a strategic alliance signed in 2012

** AstraZeneca to pay Regulus $2.5 mln and initiate early-stage study by end of 2015

** Regulus and AstraZeneca formed alliance to develop microRNA therapeutics for cardiovascular and metabolic diseases as well as oncology

** Up to Tuesday's close, the stock had risen about 140 pct since Regulus announced a collaboration agreement with Biogen (Swiss: BIIB.SW - news) Idec on August 5